FDA issues statement on Eucrisa for eczema In a controlled trial, participants receiving Eucrisa achieved clear or almost clear skin after 28 days of treatment. The FDA has approved Eucrisa ...

Atopic dermatitis is one of the most common chronic inflammatory skin diseases worldwide and is also the most common form of eczema. Although infants and children are most often affected, adults can ...

AAD New Biologic is 'Potential Blockbuster' for Eczema Treatment Dupilumab safely and effectively controls the symptoms of moderate to severe eczema over the long-term, 1-year data show. FDA approval ...

NEW ORLEANS -- A novel lower-concentration topical formulation of the PDE4 inhibitor roflumilast produced rapid improvement in mild to moderate atopic dermatitis (AD) in children and adults, two ...

Between an unrelenting itch that interrupts sleep and the social challenges of rashes that can appear anywhere on the body without warning, atopic dermatitis has many ways of raising a person’s stress ...

The panelists highlight the treatment nature of ruxolitinib, a JAK inhibitor used to treat atopic dermatitis. Casey Butrus, PharmD: I know we’re talking a lot about topical ruxolitinib, or Opzelura, ...